We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Bifidobacterium animalis subsp. lactis
The most-replicated probiotic effect on gut transit — it measurably speeds things up and adds roughly one bowel movement a week in people who are already low. But it is not a constipation cure: the two largest, best-designed trials both missed their primary endpoints, and the honest effect is hours off transit time, not a fix.
What the evidence says
Most B. lactis (BB-12 / HN019) studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 2000–2024 with a typical study size of 100 participants.
Based on 16 studies · 4 meta-analyses · 11 RCTs · 2,821 total participants
Confidence
High confidenceBy outcome
Transit-time acceleration and a modest stool-frequency increase are among the best-replicated probiotic effects, with strain-specific meta-analytic support — but the two largest, best-designed constipation trials were both null on their primary endpoints, so the honest effect is hours off transit, not a constipation treatment.
1 trial ongoing or recruiting · none completed on ClinicalTrials.gov
Registered trials show research momentum for B. lactis (BB-12 / HN019), not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Sep 2026
Under EU law (Reg. 1924/2006), EFSA reviews whether a specific health claim for B. lactis (BB-12 / HN019) meets the evidence standard. These are independent regulatory decisions on claims — not studies, and never counted toward the evidence score above.
Not authorised by EFSA
“Probiotic strain: Bifidobacterium lactis W51 Helps to increase sIgA levels”
“Probiotic strain: Bifidobacterium lactis W51 Enhances levels of beneficial bacteria in the intestine”
“Bifidobacterium animalis ssp. lactis BB-12 ® - probiotic -support your natural defences; -strenghten the natural defense”
“Probiotic strain: Bifidobacterium lactis W52 (Formerly known as Bifidobacterium infantis W52) Balances the immune system”
“Bifidobacterium lactis Bi-07 (ATCC SD5220) - probiotic - helps body's natural defences; '- helps to strenghten the natural defenses”
“Lactobacillus acidophilus (ATCC SD5221) and Bifidobacterium lactis (ATCC SD5219) '- probiotic '- Supports your immune system during the pollen season”
“Bifidobacterium animalis ssp animalis THT 010401 * Helps to strengthen natural defences * Stimulates immune system * Strengthens resistance of organism”
“Probiotic strain: Bifidobacterium lactis BI-07 (Formerly known as Bifidobacterium infantis BI- 07) Beneficially balances the intestinal immune response”
“Bifidobacterium (BB12) fortified cultured milk (Hodzeko-Amasi) Bifidobacterium cultures enhances natural immune function, helps maintain blood cholesterol”
“Not authorised” means the specific claim wording did not meet the EU’s evidence standard — often a matter of dossier or phrasing, not proof of no effect. EFSA judges marketing claims and is kept separate from our study-based evidence score.
Source: EU Register of nutrition and health claims (European Commission / EFSA) · register snapshot Feb 2013
Our research database did not respond in time, so the studies and count above cover only our curated set. This refreshes automatically.
Bifidobacterium animalis subsp. lactis is sold under several strain names — BB-12, HN019, and DN-173 010 (the Activia strain) — and its transit-time effect is among the best-replicated in the probiotic literature.
Four separate meta-analyses have examined it, and one identified HN019 and DN-173 010 as the two strongest individual strains in the whole transit literature — though they do not agree with one another: a 2022 pooled analysis found B. lactis significantly increased stool frequency while a 2020 one found it did not.
A dose-ranging trial using radiographic markers, not symptom questionnaires, showed whole-gut transit falling from 49 to 21 hours on the higher dose. But the picture is far more mixed than product marketing suggests.
The two largest dedicated constipation trials — a 229-patient triple-blind trial in 2024 and a 228-patient dose-ranging trial in 2018 — were BOTH null on their primary endpoints, and the 2024 authors explicitly wrote that they did not confirm prior positive results.
The largest trial of all (n=1,248, BB-12) missed one co-primary endpoint and its pre-specified responder threshold. Pooled analyses find no improvement in abdominal pain or bloating, and one found the transit benefit survives only in trials of 14 days or less, leaving durability unestablished.
A useful practical note: BB-12 shows a clear ceiling, with 1 billion CFU performing the same as 10 billion, so paying for higher counts buys nothing.
Transit speeds up without any change in stool weight, pH, bacterial mass or bile acids — so this is not a bulking or bile-acid mechanism. What drives the motility change upstream remains uncharacterised.
After a course of amoxicillin-clavulanate, stool acetate returned to baseline by day 30 in the BB-12 group but stayed suppressed in controls, with a smaller and less sustained loss of microbial diversity.
In infants BB-12 raised beta-defensin-2, cathelicidin LL-37 and secretory IgA while lowering faecal calprotectin, a marker of gut inflammation.
HN019 raised phagocytic capacity and natural killer cell activity in elderly subjects, with the largest changes in those whose immune responses started poorest. Laboratory biomarkers in small samples, not demonstrated clinical immunity.
How B. lactis (BB-12 / HN019) works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Studied in adults aged 63-84 with no safety signal; the transit benefit is larger in older than younger people.
624 children aged 1-4 were followed for a year on HN019-fortified milk without safety signals — though that was a prebiotic combination at a very low dose and its diarrhoea primary outcome was null (p=0.08). The constipation trial in children was also null. This applies to healthy children past infancy; see the preterm-infant entry below, which is a different situation entirely.
Do NOT give a probiotic to a preterm infant outside clinician direction. This is the one population where probiotic harm is well documented: Bifidobacterium longum sepsis has been reported with the clinical isolate genomically matched to the administered product, and in 2023 the FDA issued a Dear Healthcare Provider letter after a preterm infant given a B. longum product developed sepsis and died. That warning covers products formulated with live bacteria or yeast as a class, not one brand. Nothing about this strain's record in healthy older children transfers to a hospitalised preterm infant.
Avoid unless a clinician directs otherwise. This is a documented risk rather than a theoretical one — whole-genome work traced Lactobacillus blood isolates in ICU patients directly to the probiotic capsules they were given, and invasive Bifidobacterium infection is reported with the isolate matching the product. No published case names this strain specifically, but that is an absence of strain-level reports in a class where the mechanism is proven, not evidence of safety.
No pregnancy-specific trial exists for any of these strains. Untested rather than shown safe.
Antibiotics reduce probiotic viability. BB-12 was co-administered with amoxicillin-clavulanate and with cefadroxil in trials without any documented interaction.
Tip: Adverse-event rates matched placebo across trials including one with 1,248 participants
B. lactis (BB-12 / HN019) has an evidence score of 6/10 — moderate evidence based on 23 indexed studies, including 4 meta-analyses. The most-replicated probiotic effect on gut transit — it measurably speeds things up and adds roughly one bowel movement a week in people who are already low. But it is not a constipation cure: the two largest, best-designed trials both missed their primary endpoints, and the honest effect is hours off transit time, not a fix. Representative study: PMID 36372047.
The commonly studied dose of B. lactis (BB-12 / HN019) is 1-10 billion CFU daily for BB-12 (1 billion is enough); 10-20 billion CFU daily for HN019 if transit is the goal. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Timing is flexible for B. lactis (BB-12 / HN019) — consistent daily use matters more than the time of day. Trials used once-daily dosing, some with milk or yogurt.
B. lactis (BB-12 / HN019) is generally well-tolerated and considered safe for most healthy adults at recommended doses. Reported side effects are uncommon and include mild transient digestive changes. Use caution if any of these apply to you: Immunocompromise or immunosuppression (class-level precaution for live probiotics); Critical illness or indwelling central venous catheter.
Probiotics
Likely helpsLive microorganisms where strain selection determines outcome — Lactobacillus and Bifidobacterium strains best studied for gut, immune, and mood.
Saccharomyces Boulardii
Likely helpsAntibiotic-resistant probiotic yeast that supports digestive regularity and gut flora during travel and antibiotic use.
VSL#3 / Visbiome
Mostly mechanism / observationalAn 8-strain blend dosed in the hundreds of billions to trillions of CFU per day — roughly 45 to 7,000 times a typical 1-10 billion CFU consumer probiotic — with the largest effect size in the probiotic literature for one narrow use: maintaining remission in chronic pouchitis after ulcerative colitis surgery. It is null for IBS and Crohn's — and since 2016 the brand name no longer reliably identifies the formulation that was studied.
L. reuteri DSM 17938
Mostly mechanism / observationalThe best-evidenced probiotic for infant colic — but specifically in breastfed babies, where an individual-participant meta-analysis found a number-needed-to-treat of 2.6. In formula-fed infants the benefit disappears, and the largest single trial actually favoured placebo. Adult claims mostly belong to different L. reuteri strains entirely.
Explore: Best supplements for Body HealthBest supplements for Vitality & Longevity
Reviewed by Dr. Baher Al Hakim · Last reviewed July 2026 · evidence from 16 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research